PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 52 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $496,415 | +37.3% | 160,652 | +100.0% | 0.00% | – |
| Q2 2023 | $361,467 | +123.0% | 80,326 | +182.4% | 0.00% | – |
| Q1 2023 | $162,108 | -5.6% | 28,440 | 0.0% | 0.00% | – |
| Q4 2022 | $171,778 | -7.1% | 28,440 | 0.0% | 0.00% | – |
| Q3 2022 | $185,000 | +25.0% | 28,440 | 0.0% | 0.00% | – |
| Q2 2022 | $148,000 | -24.5% | 28,440 | 0.0% | 0.00% | – |
| Q1 2022 | $196,000 | -44.6% | 28,440 | 0.0% | 0.00% | – |
| Q4 2021 | $354,000 | -60.2% | 28,440 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $889,000 | -2.4% | 28,440 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $911,000 | -26.1% | 28,440 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,232,000 | -23.5% | 28,440 | +26.3% | 0.00% | -50.0% |
| Q4 2020 | $1,611,000 | +137.6% | 22,509 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $678,000 | – | 22,509 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
| Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
| HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
| CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
| Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
| GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
| DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
| PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |